Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

31 March 2022

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Subscribe to our newsletter

Kayentis enlists experts in oncology, neurodegenerative and metabolic disorders to...

The unquestionable value of electronic Clinical Outcome Assessments (eCOA) in...

Breaking barriers in pediatric clinical trials: perspectives from two expert...

Ensure successful outcomes with strong patient collaboration at every stage...

Empowering healing: The impact of patient partnerships in clinical trials

Collecting PRO data in leukemia clinical research: the only way...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events